Why is Biocon falling/rising?

Recent Price Movement and Market Comparison

Biocon’s share price has experienced a downward trend over the past week, falling by 2.65%, which is significantly steeper than the Sensex’s modest decline of 0.63% during the same period. Although the stock has managed a slight gain of 1.03% over the last month, this still lags behind the Sensex’s 2.27% rise. Year-to-date, Biocon’s returns stand at 5.35%, trailing the broader market’s 8.91% increase. Over the longer term, the stock has outperformed the Sensex over three years with a 39.30% gain compared to the benchmark’s 36.01%, but it has underperformed markedly over five years, registering a negative return of 13.75% against the Sensex’s robust 86.59% growth.

Intraday Performance and Trading Dynamics

On 08-Dec, Biocon’s shares touched an intraday low of ₹381.35, representing a 2.91% decline from previous levels. The weighted average price indicates that a larger volume of shares traded closer to this low, signalling selling pressure throughout the session. The stock’s price remains above its 50-day, 100-day, and 200-day moving averages, suggesting a longer-term support level; however, it is trading below its 5-day and 20-day moving averages, indicating short-term weakness. Investor participation has also waned, with delivery volumes on 05 Dec falling by 14.31% compared to the five-day average, reflecting reduced buying interest from market participants. Despite this, liquidity remains adequate, supporting trades up to ₹5.31 crore without significant price disruption.

Fundamental Factors Influencing the Decline

One of the key reasons behind the recent share price weakness is the company’s declining profitability. Over the past year, Biocon’s profits have contracted sharply by 66.6%, a significant deterioration that has weighed heavily on investor sentiment. This profit decline contrasts with the modest 1.33% return generated by the stock over the same period, highlighting a disconnect between earnings performance and share price movement. Investors appear cautious, reflecting concerns about the sustainability of earnings and the company’s near-term outlook.

Despite these challenges, Biocon maintains an attractive valuation profile. Its return on capital employed (ROCE) stands at 4.4%, and the enterprise value to capital employed ratio is a relatively low 1.7, indicating that the stock is trading at a discount compared to its peers’ historical averages. This valuation discount suggests that the market may be pricing in the risks associated with the profit decline, but also leaves room for potential upside should the company’s financial performance improve.

Institutional Investor Influence

Another stabilising factor for Biocon is its high level of institutional ownership, which currently stands at 28.71%. Institutional investors typically possess greater analytical resources and a longer-term investment horizon, which can provide some support to the stock during periods of volatility. Their continued holding indicates a degree of confidence in the company’s fundamentals despite recent profit setbacks.

Outlook and Investor Considerations

In summary, Biocon’s recent share price decline on 08-Dec is primarily driven by its underperformance relative to the broader market and sector, coupled with a significant drop in profitability over the past year. While the stock’s valuation metrics remain attractive and institutional backing is strong, the short-term technical indicators and reduced investor participation suggest caution among traders. Investors should weigh these factors carefully, considering both the company’s long-term growth potential and the immediate challenges reflected in its earnings and price action.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →